The SGLT2 inhibitor Canagliflozin disrupts the binding between PD-L1 and SGLT2, inducing PD-L1 degradation with the involvement of the E3 ubiquitin ligase Cullin3SPOP, thereby inhibiting tumor immune evasion [103]. The gene discussed is SLC5A2; the disease is neoplasm.